. 2022 Feb 8;18(12):2393–2402. doi: 10.1002/alz.12559

TABLE 2.

Effect of placebo, tadalafil, and treatment effect on CBF and blood pressure

Variable	Pre‐dose value, placebo; mean (SD)	Pre‐dose value, tadalafil; mean (SD)	Change following placebo;mean(95% CI)	Change following Tadalafil.Mean(95% CI)	Treatment effect.Mean (95% CI)
Deep gray matter CBF (mL/min/100 g)	24.2 (6.1)	24.5 (7.0)	1.75 (0.74, 2.76) P = .0010	1.79 (0.71, 2.88) p=0.0016	0.11 (−1.27, 1.48) p=0.881
Normal appearing white matter CBF (mL/min/100 g)	13.5 (4.5)	13.5 (5.2)	0.80 (0.14, 1.47) P = .0185	1.15 (0.49, 1.80) p=0.0009	0.33 (−0.54, 1.21) p=0.458
White matter hyperintensities CBF (mL/min/100 g)	9.5 (5.6)	9.4 (5.9)	0.32 (–0.48, 1.12) P = .424	1.29 (0.21, 2.38) p=0.0203	0.95 (−0.15, 2.05) p=0.0960
Total gray matter CBF (mL/min/100 g)	33.0 (7.8)	33.4 (8.7)	2.05 (0.93, 3.17) P = .0006	2.54 (1.48, 3.61) p<0.0001	0.56 (−0.90, 2.02) p=0.456
SBP (mmHg)	145 (16.0)	145 (15.6)	2.9 (–0.6, 6.4) p = 0.107	−5.0 (−8.6, −1.4) p=0.0068	−7.8 (−11.8, ‐3.9) p=0.0004
DBP (mmHg)	80.6 (8.6)	79.6 (9.4)	0.6 (–1.6, 2.7) P = .619	−4.0 (−6.0, −2.0) p=0.0002	−4.9 (−7.3, −2.4) p=0.0003

Variable

Pre‐dose value, placebo; mean (SD)

Pre‐dose value, tadalafil; mean (SD)

Change following placebo;mean(95% CI)

Change following Tadalafil.Mean(95% CI)

Treatment effect.Mean (95% CI)

Deep gray matter CBF (mL/min/100 g)

24.2

(6.1)

24.5

(7.0)

1.75

(0.74, 2.76)

P = .0010

1.79

(0.71, 2.88)

p=0.0016

0.11

(−1.27, 1.48)

p=0.881

Normal appearing white matter CBF (mL/min/100 g)

13.5

(4.5)

13.5

(5.2)

0.80

(0.14, 1.47)

P = .0185

1.15

(0.49, 1.80)

p=0.0009

0.33

(−0.54, 1.21)

p=0.458

White matter hyperintensities CBF (mL/min/100 g)

9.5

(5.6)

9.4

(5.9)

0.32

(–0.48, 1.12)

P = .424

1.29

(0.21, 2.38)

p=0.0203

0.95

(−0.15, 2.05)

p=0.0960

Total gray matter CBF (mL/min/100 g)

33.0

(7.8)

33.4

(8.7)

2.05

(0.93, 3.17)

P = .0006

2.54

(1.48, 3.61)

p<0.0001

0.56

(−0.90, 2.02)

p=0.456

SBP (mmHg)

145

(16.0)

145

(15.6)

2.9

(–0.6, 6.4)

p = 0.107

−5.0

(−8.6, −1.4)

p=0.0068

−7.8

(−11.8, ‐3.9)

p=0.0004

DBP (mmHg)

80.6

(8.6)

79.6

(9.4)

0.6

(–1.6, 2.7)

P = .619

−4.0

(−6.0, −2.0)

p=0.0002

−4.9

(−7.3, −2.4)

p=0.0003

Notes: Changes are presented with effect estimate, 95% confidence intervals, and associated P‐values. SBP and DBP data were derived from post hoc exploratory analyses (not prespecified endpoints). P‐values were not adjusted for age or sex. Analyses were based on 55 participants who completed the protocol. One participant had incomplete placebo CBF data and one other incomplete tadalafil CBF data, hence n = 53 for CBF data. For SBP and DBP, n = 55.

Abbreviations: CBF, cerebral blood flow; CI, confidence interval; DBP, diastolic blood pressure; SBP, systolic blood pressure; SD, standard deviation.